Teresa Parent

TL;DR: Tocilizumab may be a therapeutic option for the management of steroid refractory irAEs secondary to immune checkpoint blockade, however, randomized trials are needed to better elucidate the relative efficacy and safety of these agents.

TL;DR: Although most oncology nurses frequently inquire about patient physical activity, they may be less apt to provide recommendations, and a number of barriers and perceived benefits may influence physical activity promotion, especially concerning what to recommend and patient safety.

TL;DR: Combined HDR/PDT treatment for endobronchial tumors is well tolerated and can achieve prolonged local control with acceptable morbidity when PDT follows HDR and when the spacing between treatments is 1 month or less.

TL;DR: PERCIST/RECIST response is associated with improved LC and PFS in patients treated for ES-NSCLC with SBRT and pre- and post-treatment SUVmax is not predictive of disease control or survival, while ∆SUVmax did not predict for OS, PFS, LC, LRC, or DC.

TL;DR: This data indicates that suppression of immune checkpoint blockade through EMT alone or a combination of EMT and chemotherapy is an attractive treatment option in a wide spectrum of malignancies.